The research collaboration aims to advance Enterome’s EB1010, the company’s lead EndoMimics candidate designed to provide improved therapeutic outcomes for patients with these conditions.
The two companies are also committed to identifying and developing a suite of novel AllerMimics (allergen immunotherapies for food allergies) using Enterome’s Mimicry platform.
The initial focus is on peanut allergens as the basis for a new class of immunotherapies that aim to suppress allergic reactions.
“AllerMimics are a truly new class of specific antigens produced by the microbiome that are similar to food allergens and work by helping the body’s immune system tolerate those specific allergens,” explains Dr. Christoph Boni, Chief Scientific Officer of Enterome.
“We are excited to partner with Enterome on their unique microbiome drug discovery platform, striving to develop first-in-class, high-quality treatment solutions that will help patients live healthier lives.” adds Hans-Jürgen Wörle, Chief Scientific and Medical Officer of Nestlé Health Science.
40 million euros up front in cash
Under the financial terms of the agreement, Enterome will receive up to €40 million in cash and equity from Nestlé Health Science.
The Paris-based firm is also eligible to receive clinical payments and core sales payments for each licensed therapeutic candidate, plus royalties on net sales.
Further terms will have Enterome assume responsibility for lead drug discovery activities and incur related costs until the investigational new drug (IND) application.
An estimated 220 million people worldwide live with food allergies, while seven million live with inflammatory bowel disease, according to Nestlé Health Science.
Enterome’s lead candidate, EB1010, is a potent topical IL-10 inducer targeting food allergies and inflammatory bowel disease (IBD) and is slated to enter clinical trials in 2023.
The candidate was discovered using Enterome’s new Bacterial Mimicry Drug Discovery Platform, which will also be used to identify and develop novel EndoMimics as potential new therapies for food allergy-related inflammation.
“We believe that EB1010 administered orally as a pill has the potential to prevent or reduce the intensity of allergic reactions in the gut,” explains Dr. Christoph Boni, Chief Scientific Officer of Enterome.
“EB1010, which will also be evaluated in inflammatory bowel disease, will be applicable to many different types of food allergies, potentially in combination with select AllerMimics.”
“We will generate new candidates for AllerMimics using our Mimicry drug discovery platform, which has already enabled us to discover multiple first-in-class small protein and peptide drug candidates across a wide range of therapeutic areas.”
A mimicry platform
Enterome’s Mimicry drug discovery platform essentially decodes the interaction between the gut microbiome and the immune system.
The Mimicry platform uses biocomputational tools and bioassays to identify novel therapeutics for a wide range of indications from a proprietary database of 20+ million full-length gut microbiome peptides and proteins.
“Signing this collaboration further highlights both the potential and growing interest in our Mimicry platform as a source of novel immunotherapies.” adds Pierre Belichar, CEO of Enterome.
“This milestone is even more exciting following recent clinical and immunological validation of the mode of action of EO2401, our first-in-class off-the-shelf OncoMimics immunotherapy for glioblastoma and adrenal carcinoma.”
Commenting on the deal, Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners said: “Our Health for Life equity fund has supported Enterome since the company’s inception.
“As a pioneer in microbiome research, Enterome has once again demonstrated its appeal and ability to enter into co-development agreements with an international dimension.”